SCHEMBL23218619

SCHEMBL23218619

CCOC(=O)Cc1ccc(C)cc1OCc1c2cc(-c3cccc(CN)c3)ccc2nn1C(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 8/20 0.47
PLAU P00749 7/20 0.39
PLG P00747 6/20 0.39
F11 P03951 2/20 0.39
TPSB2 P20231 2/20 0.39
KLKB1 P03952 1/20 0.39
F7 P08709 1/20 0.39
PLAT P00750 3/20 0.36
ALDH1A1 P00352 3/20 0.34
POLB P06746 1/20 0.34
KDM4E B2RXH2 2/20 0.34
MAPT P10636 2/20 0.34
MAP4K4 O95819 2/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
AHR P35869 1/20 0.34
KMT2A Q03164 1/20 0.34
HPGD P15428 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852961 1.00 CFD (0.47) CFDPLAUPLGF11TPSB2
SCHEMBL23218516 0.92 CFD (0.56) CFDPLAUPLGF11TPSB2
SCHEMBL29852487 0.92 CFD (0.56) CFDPLAUPLGF11TPSB2
SCHEMBL29852920 0.92 CFD (0.46) CFDPLAUPLGF11TPSB2
SCHEMBL23218411 0.92 CFD (0.46) CFDPLAUPLGF11TPSB2
SCHEMBL23218104 0.91 CFD (0.49) CFDPLAUPLGF11TPSB2
SCHEMBL29591391 0.91 CFD (0.49) CFDPLAUPLGF11TPSB2
SCHEMBL23218475 0.90 CFD (0.49) CFDPLAUPLGF11TPSB2
SCHEMBL29852628 0.90 CFD (0.49) CFDPLAUPLGF11TPSB2
SCHEMBL23218956 0.86 CFD (0.52) CFDPLAUPLGF11TPSB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885PLAU 1119/4885PLG 421/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885PLAU 144/4885PLG 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.